Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 13/20 | 0.89 |
| ▸ | CDK2 | P24941 | 3/20 | 0.89 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.89 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.89 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.68 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.66 |
| ▸ | IDO1 | P14902 | 1/20 | 0.66 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951125 | 0.94 | FLT3 (1.00) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL30398090 | 0.94 | FLT3 (1.00) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL29365548 | 0.87 | FLT3 (0.81) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL954669 | 0.86 | FLT3 (0.78) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL29732692 | 0.86 | FLT3 (0.78) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL4509961 | 0.86 | FLT3 (0.78) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL952937 | 0.85 | FLT3 (0.77) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL30026349 | 0.84 | FLT3 (0.81) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL952936 | 0.82 | FLT3 (0.72) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL953294 | 0.82 | FLT3 (1.00) | FLT3CDK2CCNA2CCNA1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482342-B2 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
| EP-1549620-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | Sanofi-Aventis (FR) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031158-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | FLT3 255/4885CDK2 1/4885CCNA2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.